• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Datavault AI Converts $13.3 Million in Convertible Debt, Strengthens Balance Sheet

    10/2/25 6:18:56 PM ET
    $DVLT
    $SCLX
    Semiconductors
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DVLT alert in real time by email

    BEAVERTON, Ore., Oct. 02, 2025 (GLOBE NEWSWIRE) -- via IBN – Datavault AI Inc. (NASDAQ:DVLT), a pioneer in AI-driven data monetization, today announced the full conversion of certain long term notes with an aggregate original face value of $13.3 million thereby  strengthening its balance sheet substantially.

    Commenting on the debt conversion, Brett Moyer, Datavault AI Chief Financial Officer, said, "Converting these notes is an important strategic milestone and supports the accelerated launch of our independent data exchanges (IDEs) and building out our supercomputing capabilities in cooperation with IBM."

    Today's news follows the Company's announcement on September 25 that it had secured a $150 million strategic equity investment, in Bitcoin, from Nasdaq-listed biotech company Scilex (NASDAQ:SCLX) -- as biotech is a Datavault AI primary target customer market sector.

    About Datavault AI

    Datavault AI™ (NASDAQ:DVLT) is leading the way in AI driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The company's cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI's Acoustic Science Division features WiSA®, ADIO® and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization and multi-channel interference cancellation. The Data Science Division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization. Datavault AI's cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange® (IDE) enables Digital Twins, licensing of name, image and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI's technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring. The company is headquartered in Beaverton, OR. Learn more about Datavault AI at www.dvlt.ai.

    Forward Looking Statements Disclaimer

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws. Words such as "expect," "will," "anticipates," "continues" and variations of such words and similar future or conditional expressions are intended to identify forward-looking statements. Such forward-looking statements, including statements herein regarding our business opportunities and prospects, strategy, future revenue expectations, licensing initiatives, patent initiatives as well as the successful implementation of the patented technologies, are necessarily based upon estimates and assumptions that, while considered reasonable by us and our management, are inherently uncertain. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various risks and uncertainties including, but not limited to, the following: our ability to successfully utilize all intellectual property that has been issued and granted Notices of Allowance; risks regarding our ability to utilize the assets we acquire to successfully grow our market share; risks regarding our ability to open up new revenue streams as a result of the various patents mentioned in this press release; our current liquidity position and the need to obtain additional financing to support ongoing operations; general market, economic and other conditions; our ability to continue as a going concern; our ability to maintain the listing of our common stock on Nasdaq; our ability to manage costs and execute on our operational and budget plans; our ability to achieve our financial goals; the degree to which our licensees implement our technologies into their products, if at all; the timeline to any such implementation; risks related to technology innovation and intellectual property, and other risks as more fully described in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this communication based on new information, future events, or otherwise, except as required by law.

    Investor Contact

    800.491.9665

    [email protected]

    Wire Service Contact:

    IBN

    Austin, Texas

    www.InvestorBrandNetwork.com

    512.354.7000 Office

    [email protected]



    Primary Logo

    Get the next $DVLT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DVLT
    $SCLX

    CompanyDatePrice TargetRatingAnalyst
    Scilex Holding Company
    $SCLX
    1/27/2025$22.00Buy
    D. Boral Capital
    Scilex Holding Company
    $SCLX
    10/16/2024$14.00Buy
    Alliance Global Partners
    Scilex Holding Company
    $SCLX
    6/13/2024$13.00Buy
    Rodman & Renshaw
    Scilex Holding Company
    $SCLX
    10/16/2023$4.00Buy
    B. Riley Securities
    Scilex Holding Company
    $SCLX
    10/13/2023$4.00Buy
    B. Riley Securities
    Scilex Holding Company
    $SCLX
    10/9/2023$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $DVLT
    $SCLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D. Boral Capital initiated coverage on Scilex Holding with a new price target

    D. Boral Capital initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $22.00

    1/27/25 8:08:33 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alliance Global Partners initiated coverage on Scilex Holding with a new price target

    Alliance Global Partners initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $14.00

    10/16/24 8:01:57 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rodman & Renshaw initiated coverage on Scilex Holding with a new price target

    Rodman & Renshaw initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $13.00

    6/13/24 7:16:15 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DVLT
    $SCLX
    SEC Filings

    View All

    SEC Form SCHEDULE 13D filed by Scilex Holding Company

    SCHEDULE 13D - Scilex Holding Co (0001820190) (Filed by)

    10/2/25 4:05:56 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Scilex Holding Company

    424B3 - Scilex Holding Co (0001820190) (Filer)

    10/1/25 8:26:27 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Scilex Holding Company

    424B3 - Scilex Holding Co (0001820190) (Filer)

    10/1/25 8:24:17 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DVLT
    $SCLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Shah Jaisim bought $13,800 worth of shares (30,000 units at $0.46), increasing direct ownership by 27% to 139,333 units (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Issuer)

    12/18/24 7:04:41 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Executive Chairperson Ji Henry bought $8,351 worth of shares (8,888 units at $0.94), increasing direct ownership by 3% to 320,161 units (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Issuer)

    10/31/24 12:44:57 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Shah Jaisim bought $31,670 worth of shares (32,000 units at $0.99), increasing direct ownership by 41% to 109,333 units (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Issuer)

    10/29/24 6:59:31 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DVLT
    $SCLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $DVLT
    $SCLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Large owner Scilex Holding Co sold $200,000,000 worth of shares (12,500,000 units at $16.00), decreasing direct ownership by 53% to 500,000 units (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Reporting)

    9/25/25 7:49:11 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Bradley Nathaniel T disposed of 180,000 shares (SEC Form 4)

    4 - Datavault AI Inc. (0001682149) (Issuer)

    9/25/25 7:37:09 PM ET
    $DVLT
    Semiconductors
    Technology

    New insider Scilex Holding Co claimed ownership of 201,054,849 shares (SEC Form 3)

    3 - Scilex Holding Co (0001820190) (Reporting)

    9/23/25 7:48:17 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Datavault AI Selected to Power First Tokenized Dream Bowl XIV and Esports Global Championships on Jan. 11 at AT&T Stadium in Arlington, TX

    BEAVERTON, Ore., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Datavault AI Inc. (NASDAQ:DVLT), a leader in AI-driven data visualization, valuation, and monetization, today announced two strategic partnerships with Cutting Edge Sports Management and FN Esports.  These collaborations will further integrate the Company's innovative technologies into the sports and entertainment sectors, emphasizing statistical fairness in athlete selection, blockchain-based tokenization for enhanced accessibility, and the promotion of health and wellness for aspiring professionals. By selecting Datavault AI for tokenized sponsorships and a stats-based invitational process, Dream Bowl XIV is pioneering a breakthrough co

    10/3/25 3:45:00 PM ET
    $DVLT
    Semiconductors
    Technology

    Datavault AI Converts $13.3 Million in Convertible Debt, Strengthens Balance Sheet

    BEAVERTON, Ore., Oct. 02, 2025 (GLOBE NEWSWIRE) -- via IBN – Datavault AI Inc. (NASDAQ:DVLT), a pioneer in AI-driven data monetization, today announced the full conversion of certain long term notes with an aggregate original face value of $13.3 million thereby  strengthening its balance sheet substantially. Commenting on the debt conversion, Brett Moyer, Datavault AI Chief Financial Officer, said, "Converting these notes is an important strategic milestone and supports the accelerated launch of our independent data exchanges (IDEs) and building out our supercomputing capabilities in cooperation with IBM." Today's news follows the Company's announcement on September 25 that it had secur

    10/2/25 6:18:56 PM ET
    $DVLT
    $SCLX
    Semiconductors
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase

    PALO ALTO, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has repurchased 3,130,000 warrants to purchase shares of Scilex common stock having an exercise price of $0.01 per share ("Warrants") from Oramed Pharmaceuticals Inc. ("Oramed") for $13,000,000. As previously disclosed, Scilex entered into an option agreement with Oramed for the repurchase of Warrants, pursuant to which, among o

    10/1/25 9:00:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DVLT
    $SCLX
    Leadership Updates

    Live Leadership Updates

    View All

    Scilex Holding Company Strengthens Board of Directors with Appointment of Highly Accomplished Leader in Interventional and Multidisciplinary Spine, Musculoskeletal and Orthopedic Care, Annu Navani, M.D.

    PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or the "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has added to its Board of Directors a highly accomplished leader in interventional and multidisciplinary spine, musculoskeletal and orthopedic care, Annu Navani, M.D. Dr. Navani has served as the Chief Executive Officer of Comprehensive Spine and Sports Center since 2008, a leader in interventional and multidisciplinary spine, musculoskeletal, and orthopedic care. Over th

    7/23/24 9:00:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates

    PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the launch of its redesigned website showcasing the Company's growing portfolio of non-opioid pain management therapeutics. The new website can be accessed by visiting www.scilexholding.com, The features of the new and improved website include: Sleek, modern web design with dynamic elements and illustrations;An overview of the Company's science and expanded product portfolio and pr

    3/4/24 9:00:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DVLT
    $SCLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Scilex Holding Company (Amendment)

    SC 13D/A - Scilex Holding Co (0001820190) (Subject)

    4/25/24 5:25:28 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Scilex Holding Company (Amendment)

    SC 13D/A - Scilex Holding Co (0001820190) (Subject)

    3/5/24 4:22:28 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DVLT
    $SCLX
    Financials

    Live finance-specific insights

    View All

    Datavault AI Announces Entity Affiliated with CEO Acquires 10 Million Shares of DVLT Common Stock

    Datavault AI Inc. (NASDAQ:DVLT), ("Datavault AI") a pioneer in AI-driven data and acoustic sciences, today announced that EOS Technology Holdings Inc. ("EOS") has converted $3,200,000 of a convertible promissory note issued by Datavault AI to EOS into 10 million shares of common stock of Datavault AI. Datavault AI CEO Nathaniel Bradley, a recognized expert in AI and data technologies, is the chief executive officer and sole director of EOS. This investment underscores EOS' confidence in Datavault AI's patent portfolio, innovative platforms, and leadership in setting industry standards for technology licensing in acoustic, data sciences and management frameworks. "I believe Datavault AI re

    9/8/25 6:35:00 AM ET
    $DVLT
    Semiconductors
    Technology

    Datavault AI Q2 2025 Recognized Revenue of $1.7M, Reflecting 467% Year-Over-Year Growth and Booked a $2.5M Licensing Deal with Nyiax

    Establishing Annual Recurring Revenue (ARR) from Patented AI Agentic Platforms and Technology Licensing, Along with Pending Closure of API Media Acquisition, Set to Contribute to Record-Breaking Revenue Generation and Market Momentum in 2025 Management targeting annual cost-efficiency measures, yielding total savings exceeding $4 million by 2026 while optimizing for continued growth Datavault AI Inc. (NASDAQ:DVLT), a leader in AI-powered data monetization and exchange solutions, today reported strong financial performance for the second quarter ended June 30, 2025. Recognized revenue rose to $1.7 million, up significantly from $0.3 million in Q2 2024—a 467% year-over-year increase—while

    8/20/25 7:37:00 AM ET
    $DVLT
    Semiconductors
    Technology

    Datavault AI Announces Second Quarter 2025 Business Update Call

    Datavault AI Inc. (NASDAQ:DVLT), a leader in AI-powered data monetization and digital identity technologies, announced that it will issue its second quarter 2025 financial results on Tuesday, August 19, 2025. The company will host an investor conference call on Wednesday, August 20 at 9:00AM Eastern Time to review its business progress and discuss key strategic priorities. To participate in the event by telephone, please dial 1-833-366-1124 in the U.S., or 1-412-317-0702 for international callers. The conference call will also be webcast live and can be accessed from the investor relations section of the website at https://ir.datavaultsite.com/. A webcast replay will be available approx

    8/19/25 7:00:00 AM ET
    $DVLT
    Semiconductors
    Technology